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but requires systemic administration of monoclonal antibodies
(mAbs), often leading to adverse effects. To avoid toxicity,
mAbs could be expressed locally in tumors. We developed ad-
eno-associated virus (AAV) and Semliki Forest virus (SFV) vec-
tors expressing anti-programmed death ligand 1 (aPDL1)
mAb. When injected intratumorally in MC38 tumors, both
viral vectors led to similar local mAb expression at 24 h, dimin-
ishing quickly in SFV-aPDL1-treated tumors. However, SFV-
aPDL1 induced >40% complete regressions and was superior
to AAV-aPDL1, as well as to aPDL1 mAb given systemically
or locally. SFV-aPDL1 induced abscopal effects and was also
efficacious against B16-ovalbumin (OVA). The higher SFV-
aPDL1 antitumor activity could be related to local upregula-
tion of interferon-stimulated genes because of SFV RNA
replication. This was confirmed by combining local SFV-LacZ
administration and systemic aPDL1 mAb, which provided
higher antitumor effects than each separated agent. SFV-
aPDL1 promoted tumor-specific CD8 T cells infiltration in
both tumor models. In MC38, SFV-aPDL1 upregulated co-
stimulatory markers (CD137/OX40) in tumor CD8 T cells,
and its combination with anti-CD137 mAb showed more pro-
nounced antitumor effects than each single agent. These results
indicate that local transient expression of immunomodulatory
mAbs using non-propagative RNA vectors inducing type I
interferon (IFN-I) responses represents a potent and safe
approach for cancer treatment.Received 21 February 2019; accepted 6 September 2019;
https://doi.org/10.1016/j.ymthe.2019.09.016.
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Immunotherapy has recently revolutionized the field of cancer ther-
apy, representing one of the most significant breakthroughs in the
fight against cancer.1 Immunotherapies based on the use of mono-
clonal antibodies (mAbs) able to block immune checkpoints, or
genetically engineered T cells able to recognize tumor antigens, are1892 Molecular Therapy Vol. 27 No 11 November 2019 ª 2019 The Amnow allowing to treat and cure many tumors previously refractory
to conventional therapies.2
Among immune checkpoints, the programmed death 1 (PD-1)/pro-
grammed death ligand 1 (PD-L1) axis constitutes an important regu-
lator of immune responses.3,4 PD-1 is usually expressed on activated
T cells, whereas its ligand PD-L1 is mainly expressed on the surface of
antigen-presenting cells (APCs) and cells in inflamed tissues. The
interaction of PD-1 with PD-L1 leads to inhibition of T cells,
hampering their effector activity. Importantly, PD-L1 is overex-
pressed in many cancer cells, allowing tumors to escape immune sys-
tem recognition.3,5 Blocking PD-1/PD-L1 interaction with mAbs
against either PD-1 or PD-L1 has shown an impressive clinical effi-
cacy against different types of tumors, such as metastatic melanoma,
non-small-cell lung cancer, renal cancer, bladder cancer, and
Hodgkin’s lymphoma.6 Despite these remarkable therapeutic effects,
immunomodulatory mAbs are not effective in all patients and are
ineffective in some tumor types, such as pancreatic or microsatellite
stable (MSS) colon cancer. In addition, by interfering with natural
mechanisms of immune regulation, immunomodulatory mAbs given
intravenously frequently cause immune-mediated adverse effects.7,8
Onepossibility toprevent or limit these adverse reactions couldbebased
on administration of mAbs locally in tumors.9,10 In fact, both preclini-
cal11 and clinical studies have shown that it is possible to obtainerican Society of Gene and Cell Therapy.
www.moleculartherapy.orgtherapeutic benefit with intratumor injection of mAbs.12 In these cases,
much lower amounts of mAbs would be needed, because their action
could be concentrated on the tumor tissue, limiting also in thisway their
toxicity. This could be particularly interestingwhenusing combinations
of different immune checkpoint blockers, like those against PD-1 and
CTLA-4, which have improved efficacy at the cost of higher toxicity.13
An attractive approach for local mAb delivery is the use of gene ther-
apy vectors able to express mAbs inside the tumor mass. This
approach has several potential advantages, such as: (1) mAb expres-
sion could be achieved with one single vector administration, avoid-
ing repetitive injections of high doses of mAbs and lowering the price
of treatment; (2) local mAb expression could increase mAb level and
bioavailability in tumors, reducing systemic toxicity; and (3) the use
of some types of viral vectors can induce damage or inflammation
in the tumor, which could potentiate immune-stimulatory and anti-
tumor effects. In fact, several preclinical and clinical studies have
shown synergy between oncolytic viruses and immune checkpoint in-
hibitors.14–16 Oncolytic viruses can induce antitumor effects by selec-
tively destroying tumor cells, which also leads to the release of tumor
antigens that can be taken up by APCs, thus promoting antitumor-
specific T cell responses. In addition, viral infection can induce type
I interferon (IFN-I) responses, which contributes to antitumor immu-
nity and exerts synergistic effects with immunomodulatory mAbs.17
In the present studywehave used two different viral vectors todeliver an
anti-PD-L1 mAb locally in tumors. The Semliki Forest virus (SFV) vec-
tor contains as genome a positive-strand RNA able to self-replicate in
infected cells, which can be engineered to express a transgene of inter-
est.18 SFV vectors expressing cytokines such as interleukin-12 (IL-12)
have shown very potent antitumor properties in many preclinical
studies because of high expression levels, induction of apoptosis in tu-
mor cells, and stimulation of IFN-I responses.19 However, recombinant
SFV vectors enable transgene expression for only a short period of time
because of their cytopathic and non-propagative nature. In contrast, ad-
eno-associated virus (AAV)-derived vectors contain a single-strand
DNA genome that can persist episomically in infected cells, providing
very long-term transgene expression. AAV vectors have been success-
fully used in multiple clinical trials for the treatment of rare genetic dis-
eases, such as hemophilia A and B or congenital Leber’s amaurosis.20,21
In fact, twoAAV-derivedvectorshave been already approved for clinical
use in humans.22 In the present studywe have compared side by side the
antitumor efficacy of recombinant SFV and AAV vectors encoding the
same anti-PD-L1mAb in a colon adenocarcinomamodel. Interestingly,
local sustained expression of anti-PD-L1 from the AAV vector had very
low antitumor efficacy, whereas short local mAb expression accompa-
nied by IFN-I induction mediated by SFV was very effective and supe-
rior to therapies based on systemic or local mAb administration.
RESULTS
Development of AAV and SFV Vectors Expressing an Anti-PD-L1
mAb
We first determined the sequences of the variable regions of a hamster
mAb raised against mouse PD-L1,3 as described in the SupplementalMaterials and Methods. Based on these sequences, we then generated
AAV and SFV vectors expressing a chimeric hamster-mouse immu-
noglobulin G2a (IgG2a) against murine PD-L1 (see vector diagrams
in Figure 1A). To verify the expression of the recombinant mAb,
BHK cells were transfected with a plasmid containing the AAV vector
(pAAV-aPDL1 [anti-PD-L1]) or infected with viral particles (VPs)
generated with the SFV vector (SFV-aPDL1). The anti-PD-L1 mAb
was detected in supernatants of cells transfected with pAAV-aPDL1
or infected with SFV-aPDL1 by western blot (Figure 1B). A PD-L1-
specific binding ELISA was used to verify the capacity of recombinant
anti-PD-L1 antibodies to bind PD-L1. This assay showed a very
similar PD-L1 binding for the recombinant mAb expressed from
AAV or SFV vectors (Figure 1C).
AAV and SFV Vectors Mediate Local Expression of Anti-PD-L1
mAb in Tumors
To confirm that viral vectors were able to express anti-PD-L1 mAb
in vivo, they were injected intratumorally (i.t.) in C57BL/6 mice
bearing subcutaneous MC38 colon adenocarcinoma tumor nodules.
Mice received a single i.t. injection of 3  108 VPs of SFV-aPDL1
and 1011 VGs (viral genomes) of AAV-aPDL1. Other experimental
groups included mice treated i.t. with 3 108 VPs of a SFV encoding
the reporter gene b-galactosidase (SFV-LacZ) or with an equivalent
volume of saline as negative control. Expression of anti-PD-L1
mAb was analyzed by PD-L1-specific binding ELISA in samples of
serum and tumors obtained 1 and 5 days after vector injection.
Both SFV-aPDL1 and AAV-aPDL1 expressed anti-PD-L1 mAb in tu-
mors, reaching similar levels at day 1 (Figure 1D). These levels
decreased at day 5 in the case of SFV-aPDL1, probably because of
the cytopathic effect of this vector, whereas anti-PD-L1 mAb concen-
tration remained significantly elevated for AAV-aPDL1 at day 5. mAb
levels detected in serum with both vectors were very low at day 1, but
increased at day 5 in mice treated with AAV-aPDL1, whereas they
were almost undetectable in animals that had received SFV-aPDL1
(Figure 1E). As expected, no mAb expression was observed in the
SFV-LacZ and saline groups.
SFV-aPDL1 Elicits Higher Antitumor Effects Than AAV-aPDL1
against Colon Adenocarcinoma Tumors
To evaluate the antitumor potential of SFV and AAV vectors express-
ing antiPD-L1 mAb, mice bearing subcutaneous MC38 tumors with
an average diameter of 3–3.5 mm were treated with a single i.t. injec-
tion of 3  108 VPs of SFV-aPDL1 or 1011 VGs of AAV-aPDL1,
because these doses had shown to provide similar mAb expression
in tumors (Figure 1D). As controls, tumor-bearing mice were treated
with either 3  108 VPs of SFV-LacZ or an equivalent volume of
saline. In parallel, additional groups of mice were treated with three
doses of SFV-aPDL1 or SFV-LacZ (3  108 VPs each), administered
every 48 h to determine whether the antitumor effect of this short-
term expression vector could be enhanced by repeated administra-
tions. The efficacy of treatment was evaluated by measuring tumor
size every 3–4 days (Figure 2A) andmonitoring survival in each group
(Figure 2B). SFV-aPDL1 showed a clear antitumor effect that resulted









































































































Figure 1. AAV and SFV Viral Vectors Express Anti-PD-L1 mAb in Cultured Cells and in Tumors In Vivo
(A) Schematic representation of AAV and SFV vectors expressing anti-PD-L1mAb. In SFV-aPDL1, black rectangles at the ends represent 50 and 30 viral sequences necessary
for replication, and the black arrow represents the SFV subgenomic promoter (the replicase gene is not to scale). (B and C) BHK cells were transfected with AAV-aPDL1
plasmid or infected with the indicated SFV vectors, or mock infected, and the supernatants were collected 48 h later and analyzed as indicated. (B) Western blot was
performed under non-reducing (DTT) or reducing (+DTT) conditions using an anti-mouse IgG peroxidase-conjugated antibody. Red and blue arrows show the complete
mAb and the HC of anti-PD-L1 mAb, respectively (LC could not be detected due to low affinity of secondary antibody for lambda LC). (C) A PD-L1-binding ELISA was
performed by coating ELISA plates with recombinant PD-L1-Fc and incubating them with serial dilutions of supernatants from cells transfected or infected with the indicated
vectors. In order to compare binding of anti-PD-L1 mAb expressed by both vectors, we previously quantified IgG in each sample (using a total mouse IgG ELISA kit) and
adjusted mAb concentrations to 40 ng/mL, fromwhich 1:4 dilutions were tested. For themock-infected sample, the first dilution was prepared with a volume equivalent to the
one used for the samplewith lowermAb concentration. (D and E) C57BL/6mice bearing subcutaneousMC38 tumors having an average diameter of 5.5mm received a single
intratumoral dose of 1011 VGs (AAV-aPD-L1), 3 108 VPs (SFV-aPD-L1 and SFV-LacZ), or the same volume of saline. The amount of recombinant anti-PD-L1 mAb present
in tumor extracts (D) and serum (E) was determined at the indicated times using a PD-L1-binding ELISA (n = 5 for each time point). Asterisks above bars indicate comparison
of each group with saline. *p < 0.05; **p < 0.01. One representative experiment out of two performed is shown. 2A, foot-and-mouth disease virus 2A autoprotease; EF1a,
human elongation factor 1a promoter; f, furine protease cleavage site; HC, mAb heavy chains; ITR, AAV inverted terminal repeats; LC, mAb light chains; ns, not significant;
pA, synthetic polyadenylation sequence. Data represent the mean + SEM.
Molecular Therapyin 43% of tumors, compared with only 14% in the case of AAV-
aPDL1. In fact, this last vector did not show a significant effect on tu-
mor reduction when compared with the saline control group. On the
other hand, the antitumor effect of SFV-aPDL1 slightly improved
when three doses of vector were administered, reaching 57% of com-
plete remissions, although survival was not significantly increased. All
animals that rejected tumors remained tumor-free for the rest of the
experiment (>2–3 months). Interestingly, SFV-LacZ showed a low
antitumor effect that increased when mice received three doses of
vector, possibly because of the induction of apoptosis and IFN-I1894 Molecular Therapy Vol. 27 No 11 November 2019responses induced by SFV, as will be discussed later. However, the
antitumor effect provided by this control SFV vector was significantly
lower than the one obtained with SFV-aPD-L1 (Figures 2A and 2B).
In order to determine whether treatment with vectors expressing anti-
PD-L1 mAb induced immunological memory, mice that had rejected
tumors after SFV-aPDL1 treatment were rechallenged subcutane-
ously with MC38 cells. No development of tumors was observed in
cured animals, in contrast with naive controls, indicating that the vec-
tor had induced immunological memory, which could protect against
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Figure 2. Evaluation of Antitumor Efficacy of AAV and SFV Viral Vectors Expressing Anti-PD-L1 mAb in MC38 Subcutaneous Tumors
A total of 5  105 MC38 cells were inoculated subcutaneously into the right flank of C57BL/6 mice and approximately 7 days later (day 0), when the average diameter was
3–3.5 mm, animals received one intratumoral dose of 108 VGs of AAV-aPDL1 or 3 108 VPs of SFV-aPDL1or SFV-LacZ (1). A control group received the same volume of
saline. Two additional groups received three intratumoral doses of SFV-aPDL1 or SFV-LacZ given on days 0, 2, and 4 (3). (A) Evolution of tumor size. Data represent the
mean tumor size (mm2) + SEM. (B) Survival after treatment. (C) Survival after tumor rechallenge. Mice treated with SFV-aPDL1 (1 or 3) that rejected tumors (n = 7) were
rechallenged 2–3 months later with 5 105 MC38 cells, and survival was analyzed using naive mice that received the same amount of tumor cells as controls (n = 8). For (A)
and (B), one representative experiment (n = 7) out of three performed is shown (in B the statistical analysis was performed using pooled data from two independent
experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. ns, not significant.
www.moleculartherapy.orgpossible recurrences (Figure 2C). We also determined whether treat-
ment with SFV-aPDL1 could induce abscopal effects in non-treated
nodules. Mice receiving SFV-aPDL1 in one tumor showed a signifi-
cant reduction of tumor size both in treated and in non-treated nod-
ules (Figure S1A), indicating that this kind of therapy can induce
abscopal effects. We also observed significantly higher survival in
SFV-aPDL1-treated mice (Figure S1B), although long-term survival
was not reached, most likely because the abscopal effect was not
potent enough to eliminate non-treated tumors.
To investigate whether SFV-aPDL1 also had antitumor efficacy in
other types of tumors, we proceeded to test it in a melanoma model
that is particularly resistant to PD-L1 blockade, such as B16-ovalbumin
(OVA) tumors derived from the B16F10 melanoma cell line.23 For this
purpose, C57BL/6 mice carrying subcutaneous B16-OVA tumors were
injected i.t. with a single dose of SFV-aPDL1 (3 108 VPs). As control
groups, we included mice in which tumors were treated with the same
dose of SFV-LacZ or saline (mock-treated group). SFV-aPDL1 showed
clear antitumor efficacy that resulted in a significant delay of tumor
growth after the injection of the virus (Figures S2A and S2B). The
SFV-aPDL1 vector also increased significantly the survival of treated
animals compared with saline or SFV-LacZ (Figure S2C).SFV-Mediated Local Expression of Anti-PD-L1 mAb Induced
Higher Antitumor Effects Than Systemic or Local Administration
of the Same mAb
To evaluate whether local expression of anti-PDL1mAb by SFV could
be an alternative to the administration of the same mAb as recombi-
nant protein, we carried out a comparative study of these two strate-
gies. For this purpose, mice bearing MC38 subcutaneous tumors were
treated with a single i.t. injection of SFV-aPDL1 (3  108 VPs) or
received anti-PD-L1 mAb either i.t. or intraperitoneally (i.p.). For
the i.t. route, we used two doses of 100 ng mAb given with a 48-h in-
terval, each dose being approximately 5-fold higher than the amountexpressed by SFV-aPDL1 in the tumor as determined in Figure 1D.
For the i.p. route, we used a standard mAb dosing (three doses of
100 mg given every 72 h). SFV-aPDL1 was clearly more potent than
anti-PD-L1 mAb given i.t. (Figures 3A–3C). In the case of anti-PD-
L1 mAb given i.p., it was able to provide a reduction in tumor growth
that was less potent than SFV-aPDL1, but this last vector provided a
significantly higher survival (Figure 3C). These results suggest that
SFV-mediated local inflammation in combination with anti-PD-L1
expression is responsible for the higher antitumor effect of this vector.
To test this hypothesis, we evaluated the antitumor efficacy of SFV-
LacZ given i.t. in combination with anti-PD-L1 mAb delivered i.p.
This combination therapy induced a significant reduction in tumor
growth with 25% complete regressions, whereas no regressions
were observed with each single agent (Figures S3A and S3B). In addi-
tion, combination therapy significantly increased survival, in contrast
with each single agent (Figure S3C).SFV-aPDL1 Induces Type I IFN Responses Locally in Tumors
As shown before, SFV-aPDL1 was more potent than AAV-aPDL1 at
inducing antitumor responses (Figure 2), despite the fact that the
AAV vector expressed the antiPD-L1 mAb at similar levels and for a
longer time (Figure 1D). One possible mechanism to explain the higher
antitumor effect of SFV-aPDL1 could be related to the fact that SFV
RNA replication can induce IFN-I responses locally in the tumor,
which have been described to potentiate checkpoint inhibitors’ anti-
tumor effects.17 To evaluate this possibility, we analyzed the induction
of IFN-stimulated genes (ISGs) in mice bearing MC38 tumors that
were injected i.t.with the following vectors: SFV-aPDL1, SFV-LacZ
(3  108 VPs), or AAV-aPDL1 (1011 VGs). Tumors were processed
17 h after treatment and analyzed by qRT-PCR with primers specific
for ISGs, including 20-50-oligoadenylate synthetase 2 (OAS2), Mx1,
TRIM, and STAT1, as well as for SFV replicase (Figure 4). Notably,
the level of ISGs was significantly upregulated in tumors treated with















































































































Figure 3. SFV-aPDL1 Given Intratumorally Showed Greater Antitumor Effect Than Anti-PDL1 mAb Administered Locally or Systemically
C57BL/6 mice bearing subcutaneous tumors were inoculated intratumorally with a single dose of SFV-aPDL1 (3  108 VPs), as described in Figure 2. In parallel, mice with
similar tumors received three intraperitoneal (i.p.) doses of 100 mg of anti-PDL1 mAb on days 0, 3, and 6, or two intratumoral (i.t.) doses of 100 ng of anti-PDL1 mAb on days
0 and 2.Mice treated with saline were used as negative control. (A) Evolution of tumor size (mm2) along time for each individual mouse. The fractions in the right lower corner of
each graph indicate the number of complete regressions/total number of mice in each group. Dashed lines indicate the times of mAb administrations. (B) Mean tumor size
evolution ± SEM. (C) Survival after treatment (pooled data from two independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. One representative
experiment out of two performed is shown. ns, not significant.
Molecular Therapyconfirming the induction of IFN-I responses by SFV. The detection of
high levels of viral RNA in SFV-treated tumors confirmed the local
replication of these vectors (Figure 4).
Analysis of PD-L1 Expression in Tumors
The higher antitumor effects mediated by SFV-aPDL1 in comparison
with SFV-LacZ are likely mediated by PD-L1 blocking on tumor cells.
We confirmed that both MC38 and B16-OVA cells were able to ex-
press PD-L1 in vitro. As shown in Figure S4A, both tumor cell lines
showed basal PD-L1 levels that significantly increased when incu-
bated with IFN-gamma, with a higher increase in B16-OVA. We
also confirmed that both types of cells expressed PD-L1 in tumors im-
planted in vivo (Figure S4B). Interestingly, treatment with SFV vec-
tors significantly increased PD-L1 in B16-OVA tumors, which could
be mediated by the induction of IFN-I responses. This effect was not
observed in MC38 tumors, suggesting that upregulation of PD-L1 in
these cells is less potent.
SFV-aPDL1 Induces Potent Cellular Immune Responses with
Elevation of Co-stimulatory and Co-inhibitory Molecules
In order to characterize immune responses induced by SFV-aPDL1,
mice bearing MC38 tumors received by i.t. injection 3  108 VPs of1896 Molecular Therapy Vol. 27 No 11 November 2019this vector. Animals were sacrificed 5 days later, and immune cell sub-
populations from tumors, tumor draining lymph nodes (TDLNs),
and peripheral blood were analyzed by multicolor flow cytometry
analysis. As control for this study, we used mice injected with the
same dose of SFV-LacZ or with an equivalent volume of saline solu-
tion. We also included a group of mice inoculated with AAV-aPDL1
as an additional control. The fact that this vector expressed levels of
anti-PD-L1 mAb similar to SFV-aPDL1, but induced only marginal
antitumor effects could provide information about the immunolog-
ical changes mediated by the mAb.
SFV-aPDL1 was able to significantly increase total CD8 T cells in tu-
mors, TDLNs, and peripheral blood (Figures 5A–5C, left graphs). Total
CD4T cells were also increased by SFV-aPDL1, reaching significance in
TDLNs and blood (Figures 5A–5C, right graphs). Interestingly, tumor-
specific CD8 cells, which were measured using MHC class I tetramers
specific for a MC38 dominant epitope (tumor-associated KSPWFTTL
peptide [KSP]), were more elevated in tumors and TDLNs from SFV-
aPDL1-treated mice, suggesting that this vector was inducing a more
potent local response. Tumor-specific CD8 cells were also detected in
blood in SFV-treatedmice (Figure 5C, central graph). In order to deter-
































































































































Figure 4. Analysis of the Expression of Genes Induced by Type I IFN in MC38 Subcutaneous Tumors
C57BL/6 mice bearing subcutaneous MC38 tumors received a single intratumoral dose of 3 108 VPs (SFV-aPD-L1 and SFV-LacZ), 1011 VGs (AAV-aPD-L1), or the same
volume of saline. Tumor samples were extracted and processed 17 h after treatment as described in theMaterials andMethods. Finally, they were analyzed by qRT-PCRwith
primers specific for the indicated genes. Asterisks above each bar indicate the statistical comparison of each group with the saline group. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. ns, not significant. Data represent the mean + SEM.
www.moleculartherapy.orgexpression of the CD62L surface marker, whose downregulation was
associated with the acquisition of an effector-like phenotype. As
observed in Figure S5A, both total and KSP-specific CD8 tumor cells
from SFV-aPDL1-treated mice had a significantly lower level of
CD62L compared with all of the other groups.
We then proceeded to analyze the percentage of CD8 and CD4 tu-
mor-infiltrating T cells (TILs) expressing co-stimulatory (CD137,
OX40, and inducible T cell costimulator [ICOS]) and co-inhibitory
(PD-1, LAG-3, 2B4, and TIM-3) molecules. Interestingly, the per-
centage of CD137- and OX40-positive CD8 TILs was increased in
mice treated with SFV vectors, with no significant differences
observed between SFV-aPDL1 and SFV-LacZ (Figure 6A). This trend
was also observed in KSP-specific CD8 TILs for both markers,
although it did not reach significance. No significant differences
were observed for ICOS (Figure S6). Regarding co-inhibitory
markers, an increase of LAG-3 was detected in total CD8 TILs
from mice treated with SFV vectors (Figure 6B). Despite its lack of
antitumor efficacy, AAV-aPDL1 seemed to diminish LAG3 in CD8
cells. No relevant changes in the expression of PD-1, 2B4, and
TIM-3 in CD8 TILs were observed between groups (Figure 6B; Fig-
ure S6). Regarding CD4 TILs, we observed a significant downregula-
tion of PD-1 and TIM-3 in SFV-treated mice (Figure 6B; Figure S6).
All together, these results suggest that in contrast with AAV-aPDL1,
SFV-aPDL1 was able to promote tumor infiltration by T cells,increasing the number of tumor-specific CD8 cells with an effector
phenotype. Changes in co-stimulatory and co-inhibitory markers
were similar between SFV-aPDL1 and SFV-LacZ, suggesting that
they were probably due to the self-replication nature of the SFV
RNA vector, which is able to promote inflammation and IFN-I
responses by itself as shown before (Figure 4).24
In order to determine whether SFV-aPDL1 was inducing similar
changes in B16-OVA, we analyzed immunological markers in TILs
from these tumors. In this case, we observed a significant upregulation
of both total and tumor-specific CD8 cells in mice treated with SFV-
aPDL1, in contrastwith those treatedwith SFV-LacZ or saline, confirm-
ing the results observed inMC38 (Figure 7). A lower level of CD62Lwas
also observed inCD8 cells fromSFV-aPDL1-treated tumors, suggesting
an effector-like phenotype (Figure S5B). In addition, both SFV-aPDL1
and SFV-LacZ induced a reduction of PD-1 in tumor-specificCD8 cells,
although it reached significance only with this last vector (Figure S7A).
However, in contrast withMC38, no relevant changes were observed in
LAG-3 and CD137 (Figures S7B and S7C), indicating tumor-inherent
differences despite the fact that both models responded to treatment.
Intratumoral Injection of SFV-aPDL1 Synergizes with Systemic
CD137 Co-stimulation, But Not with LAG-3 Inhibition
The upregulation of some co-stimulatory (CD137 and OX40) and









































































































































































































































































































































Figure 5. Analyses of CD8 and CD4 T Cells in MC38 Tumors, Lymph Nodes, and Blood
C57BL/6 mice bearing subcutaneous MC38 tumors were inoculated with the indicated vectors or saline as described in Figure 1D. Five days after the administration of
vectors, tumors and tumor draining lymph nodes (TDLNs) were excised and digested, and single-cell suspensions were analyzed by flow cytometry. Blood was collected on
the same day and analyzed by flow cytometry. Data represent the mean (n = 6) ± SEM of total CD8 (left graphs), tumor-specific CD8 (MC38 Tetr+, central graphs), and CD4
T cells (right graphs) in tumors (A), TDLNs (B), and blood (C). Gating strategies are shown in Figure S9. Asterisks above each bar indicate the statistical comparison of each
group with the control saline group. Other comparisons are indicated by horizontal bars. +p < 0.1; *p < 0.05; **p < 0.01. ns, not significant.
Molecular TherapySFV-aPDL1 suggested that this therapy could benefit from a combi-
nation with mAbs able to stimulate or block these receptors, respec-
tively. To test our hypothesis, we treated mice bearing MC38 subcu-
taneous tumors with 3  108 VPs of SFV-aPDL1 given i.t. combined
with either anti-CD137 or anti-LAG-3 mAbs given i.p. In this case we
used tumors slightly larger than in previous experiments (4–5 mm of
average diameter) in order to increase our therapeutic window.
Control groups received only mAbs, only the vector, or saline. Despite
the upregulation of LAG-3 induced by SFV vectors, combination with
anti-LAG-3 mAb contributed only slightly to reducing the progres-
sion of tumors (Figure 8). The anti-LAG-3 single treatment did not
have any therapeutic effect in this model as had been previously
described.25 However, combination of i.t. SFV-aPDL1 and systemic
anti-CD137 mAb showed a very potent antitumor effect that resulted
in elimination of 50% of tumors with long-term survival (Figure 8). In1898 Molecular Therapy Vol. 27 No 11 November 2019contrast, SFV-aPDL1 or anti-CD137 mAb given as single agents were
able to induce only 25% and 11% of complete regressions, respec-
tively. It has been previously reported that resistance to anti-CD137
therapy can be overcome by PD-1/PD-L1 blockade.26 To determine
whether anti-CD137 target cells could be affected by this blockade
in our model, we analyzed TILs from MC38 tumors, observing that
almost 100% of CD137-positive CD8 cells were also positive for
PD-1 (Figure S8). This could partially explain the beneficial effects
of co-stimulation via CD137 and simultaneous relief from PD-1 inhi-
bition using SFV-aPDL1, as observed in this study.
DISCUSSION
In this study we evaluated the antitumor efficacy of AAV and SFV
viral vectors able to express an anti-PD-L1 mAb locally in tumors.



































































































































































































































































































































































































































Figure 6. Analyses of Co-stimulatory and Co-inhibitory Immunological Markers on MC38 Tumor T Cells
Tumor-infiltrating lymphocytes obtained as described in Figure 5 were analyzed by flow cytometry with antibodies specific for the immunological co-stimulatory markers
CD137 and OX40 (A) and for immunological co-inhibitory markers PD-1 and LAG3 (B). Data show levels (mean ± SEM, n = 6) of each marker in total CD8 T cells (left graphs),
tumor-specific CD8 T cells (MC38 Tetr+, central graphs), and total CD4 T cells (right graphs). Asterisks above each bar indicate the statistical comparison of each group with
the control saline group. Other comparisons are indicated by horizontal bars. *p < 0.05; **p < 0.01; ***p < 0.001. ns, not significant.
www.moleculartherapy.orgproperties for cancer immunotherapy. AAV is a single-strand DNA
vector that is easy to produce at high scale and has been extensively
used in human patients without showing toxicity.27 The main advan-
tage of this vector is the fact that it can provide long-term expressionof the desired transgene, which might be required to sustain appro-
priate levels of immunomodulatory mAbs inside tumors. AAV vec-
tors have also been successfully used for cancer immunotherapy in
























































































Figure 7. Analyses of CD8 and CD4 T Cells in B16-OVA Tumors
A total of 5  105 B16/OVA cells were inoculated subcutaneously into the right flank of C57BL/6 mice and 6 days later, when tumors had an average diameter of 4–5 mm,
animals received one intratumoral dose of 3  108 VPs of the indicated SFV-derived vectors or an equivalent volume of saline. Five days after the administration of vectors,
tumors were excised, digested, and single-cell suspensions were analyzed by flow cytometry. Data represent themean (n = 6) ±SEMof total CD8 (left graphs), tumor-specific
CD8 (B16-Tetr+, central graphs), and CD4 T cells (right graphs) in tumors. Asterisks above each bar indicate the statistical comparison of each group with the control saline
group. Other comparisons are indicated by horizontal bars. *p < 0.05; **p < 0.01; ***p < 0.001. ns, not significant.
Molecular TherapyIL-1228 or IL-27.29 SFV is an RNA vector that can replicate in infected
cells, leading to very high expression levels of desired transgenes.18 In
contrast with AAV, SFV vectors can provide only a very short trans-
gene expression, due to the fact that they are unable to propagate and
induce apoptosis in infected cells. Despite short expression, SFV vec-
tors expressing IL-12,30 IFNa,31 or a combination of the dendritic cell
differentiation factor Flt3L and chemokine XCL132 have shown
potent antitumor effects against a variety of preclinical models,
including spontaneous tumors in the case of SFV-IL-12.33,34 One of
the key mechanisms by which SFV can exert its antitumor action is
based on the potent induction of IFN-I responses in infected cells.
In fact, we have shown that IFN-I induction is strictly required for
the therapeutic effects of SFV-IL-12 and is dependent on IPS-1 and
Trif signaling and independent of the Myd88 pathway.24 Given that
previous studies had shown that the antitumor effect of immunomod-
ulatory mAbs could be highly potentiated with agents able to induce
IFN-I responses, such as polyinosinic:polycytidylic acid (poly(I:C)) or
oncolytic viruses,17,35,36 we reasoned that an SFV vector able to ex-
press an anti-PD-L1 mAb could combine both properties in a single
agent. In addition, because it has been shown that IFNa and IFNb can
induce PD-L1 expression in tumor cells,17 “arming” an IFN-I-
inducing vector with an anti-PD-L1 mAb could enhance its anti-
tumor potential. One drawback of this strategy could be that the
anti-PD-L1 mAb will be expressed transiently in the tumor, as we
observed in mice treated with SFV-aPDL1, in which expression was
not detected after 24 h (Figure 1D). In contrast, mice that received
AAV-aPDL1 were able to express the mAb during at least 5 days.
However, despite the much shorter, but quantitatively similar, mAb
expression of SFV-aPDL1, this vector was able to induce more potent
antitumor effects than AAV-aPDL1 in the MC38 colon adenocarci-
noma model (Figure 2).
The effect of SFV-aPDL1 was slightly improved by providing three
doses of the vector given every 48 h, in an attempt to maintain anti-
PD-L1 levels in the tumor for longer times. In agreementwith this result,
we had previously observed that the antitumor effects of SFV-IL-121900 Molecular Therapy Vol. 27 No 11 November 2019could also be improved with repetitive administrations of the vector.37
SFV-aPDL1 was also able to inhibit the growth of B16-OVA tumors,
although in this case the antitumor effect was transient in most mice,
resulting in 11% complete regressions. B16-OVA tumors have shown
in previous studies to be more resistant to therapies based on SFV vec-
tors compared with MC38.38 In addition, several studies performed by
us and others have shown thatmAbs able to block the PD-1/PD-L1 axis
are not very efficient in this tumormodel, which could explain the lower
efficacy of SFV-aPDL1.39 Interestingly, SFV vectors induced higher
PD-L1 expression in B16-OVA tumor cells compared withMC38 (Fig-
ure S4), which could explain in part why SFV therapy was less potent in
B16-OVA, because higher amounts of antiPD-L1 are probably needed
in this model to overcome this resistance mechanism.
Comparison of local SFV-aPDL1-based therapy with systemic
administration of anti-PD-L1 mAb was important to demonstrate
that local mAb delivery could reach the same or slightly higher ther-
apeutic effects, as it was the case (Figure 3). It is important to note
that, as observed in mice treated with AAV-aPDL1, i.t. delivery of
the anti-PD-L1 mAb without the inflammation induced by SFV
had negligible antitumor effects. In fact, by combining local SFV-
LacZ administration and systemic anti-PDL1 mAb, we observed
higher antitumor effects than with each separated agent (Figure S3).
In order to get some insights on the mechanisms by which SFV-
aPDL1 provided stronger antitumor responses than AAV-PDL1, we
analyzed the tumor microenvironment of treated mice at two levels,
namely, the analysis of IFN-I responses and the characterization of
immune cells; these were also analyzed both in blood and in TDLNs.
As expected, SFV-aPDL1, and also control vector SFV-LacZ, were
able to significantly upregulate different ISGs, which included Mx1,
OAS-2, TRIM-21, and STAT-I (Figure 4). However, AAV-aPDL1
did not change the expression of any of these genes, being unable
to benefit from IFN-I responses. The induction of an IFN-I response
by SFV is most likely due to its RNA replication in infected cells, as
has been previously reported.24
A
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Figure 8. Treatment Efficacy of SFV-aPDL1 in
Combination with Anti-CD137 and Anti-LAG3 mAbs
Mice bearing subcutaneous MC38 tumors (4–5 mm of
average diameter) were inoculated with one intratumoral
dose of SFV-aPDL1 (3  108 VPs) or saline (day 0). Then,
one third of mice were intraperitoneally injected with anti-
CD137 (days 0 and 6) or with anti-LAG3 (days 3, 6, and 9).
(A) Graphs show the evolution of tumor size over time for
each individual mouse. The fractions in the right lower
corner of each graph indicate the number of complete
regressions/total number of mice for each group. (B)
Data represent the mean tumor size for all groups + SEM
(n = 8–9). (C) Survival after treatment. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. One representative experi-
ment out of two performed is shown. ns, not significant.
www.moleculartherapy.orgRegarding immunological changes, a significantly higher infiltration
of tumor-specific CD8 cells with effector phenotype was observed in
MC38 tumors receiving SFV-aPDL1, but not in those treated with
AAV-aPD-L1 or control SFV-LacZ vector (Figure 5; Figure S5). A
similar effect was also observed in B16-OVA tumors (Figure 7), sug-
gesting that to unleash potent immune responses, both expression of
anti-PD-L1 mAb and induction of IFN-I responses were required.
Interestingly, in MC38 tumors, SFV-aPDL1 and SFV-LacZ upregu-
lated several co-stimulatory and co-inhibitory receptors in tumor
CD8-infiltrating cells to similar levels, suggesting that these changes
are mediated by the induction of IFN-I responses or by other mech-
anisms related to SFV infection per se. These last changes provided
clues for possible combinatorial treatments. In the present work we
tested the combination of local injection of SFV-aPDL1 with sys-
temic administration of either anti-CD137 or anti-LAG-3 mAbs.
Unexpectedly, anti-LAG-3 mAb was unable to enhance the anti-
tumor activity of SFV-aPDL1. This is in contrast with other studies
where a combination of anti-PD-1 and anti-LAG-3 mAbs was high-
ly synergistic against MC38 tumors.25 Although we do not have a
clear explanation for the lack of synergy in our model, it is possible
that higher levels of anti-PD-L1 than the ones provided locally byMolecularour vector were required for this effect. Finally,
we were able to observe an enhancement of the
antitumor response by combining SFV-aPDL1
and anti-CD137 mAb. Synergy between anti-
PD-L1 and anti-CD137 mAbs had been previ-
ously reported and is probably due to the
concomitant stimulation of anti-CD137 on
activated CD8 T cells and the inhibition of
the interaction of these cells with PD-L1 on
tumor cells.40 In fact, we observed that almost
the totality of CD137+ CD8 TILs from MC38
tumors also expressed PD-1 on their surface
(Figure S8), suggesting that anti-CD137 ther-
apy could benefit from PD-1/PD-L1 blockade,
as shown previously by Hirano and col-
leagues.26 Given the toxicity reported by anti-
CD137 agonist mAbs in clinical trials,41 itwould be highly interesting to evaluate the possibility to also express
this mAb locally in tumors from SFV vectors.
Although previous reports have shown that expression of PD1/PD-L1
blocking antibodies from viral vectors can provide antitumor activity
in preclinical tumormodels, these studies were based on the use of on-
colytic viruses, such as vaccinia andmeasles virus.42,43 These agents, in
contrast with SFV vectors, can propagate in tumors, inducing strong
antiviral responses that could limit their efficacy and prevent readmi-
nistration. In addition, the presence of neutralizing antibodies against
these viruses is common in the general population,44,45 which has not
been reported for SFV. Our studies comparing SFV and AAV also
show that the choice of a viral vector is relevant for antitumor success,
regardless of the level and duration of transgene expression.
In summary, our results show that local and short expression of
immunomodulatory mAbs could be highly effective when expressed
from vectors able to induce IFN-I responses, like SFV. This kind of
strategy could offer a high degree of versatility, because it might allow
i.t. expression of different combinations of mAbs or cytokines in a
transient manner, reducing their possible toxicity.Therapy Vol. 27 No 11 November 2019 1901
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Cell Lines and Animals
BHK cells (ATCC-CCL10) were cultured in GMEM-BHK21 medium
(Thermo Fisher, MA, USA) supplemented with 5% fetal bovine
serum (FBS), 10% tryptose phosphate broth, 2 mM glutamine,
20 mM HEPES, 100 mg/mL streptomycin, and 100 U/mL penicillin
(BHK complete). HEK293T (ATCC-CRL-3216) cells were cultured
in DMEM medium (GIBCO) supplemented with 10% FBS, 2 mM
glutamine, 100 mg/mL streptomycin, and 100 U/mL penicillin.
Hamster hybridoma 10B53 was kindly provided by Dr. Lieping
Chen (Yale University, New Haven, CT, USA) and grown in RPMI
1640 + GlutaMAX medium (GIBCO) with 10% FBS, 0.5 mM sodium
pyruvate, 5 mM 2-mercaptoethanol, 1% Condimed (Roche), HT
Media supplement (GIBCO), 100 mg/mL streptomycin, and
100 U/mL penicillin. MC38 cells were a kind gift from Dr. Karl E.
Hellström (University of Washington, Seattle, WA, USA) and were
grown in DMEM (GIBCO BRL, UK) supplemented with 10% FBS,
2 mM glutamine, and antibiotics. B16-OVA cells were kindly pro-
vided by Dr. Lieping Chen and cultured in RPMI 1640 + GlutaMAX
medium supplemented with 10% FBS and 50 mM 2-mercaptoethanol.
Both tumor cell lines were authenticated by Idexx Radil (Case 6592-
2012) in February 2012.
Four-week-old female C57BL/6 mice were purchased from Envigo
(Barcelona, Spain). Animal studies were approved by the Universidad
de Navarra ethical committee (study 099-14 and 024-18) for animal
experimentation under Spanish regulations.
Production of Viral Vectors
To produce AAV-aPDL1 VPs with serotype AAV8, thirty 150-cm2
flasks containing confluent HEK293T cells were co-transfected using
linear polyethylenimine 25 kDa (Polysciences, Warrington, PA, USA)
with two different plasmids: pAAV-aPDL1 and pDP8.ape (Plasmid
Factory, Germany), which contains adenoviral helper genes plus
AAV2 rep and AAV8 cap genes. After 72 h of incubation, the superna-
tant was collected, treated with polyethylene glycol solution (PEG8000,
8% v/v final concentration) for 48–72 h at 4C, and centrifuged at
3,000 rpm for 15 min. The pellet containing AAV VPs from the super-
natantwas resuspended in lysis buffer andkept at80C.Cells contain-
ing AAV VPs were collected, treated with lysis buffer (50 mM Tris-Cl,
150 mMNaCl, 2 mMMgCl2, 0.1% Triton X-100), and kept at80C.
After three cycles of freezing and thawing supernatants and cell lysates,
VPs were purified by ultracentrifugation in an iodixanol gradient as
described previously.46 Finally, the purified virus was concentrated us-
ing Amicon Ultra Centrifugal Filters-Ultracel 100K (Millipore). AAV
vector titers were determined by qPCR for VG copies extracted from
DNase-treated VPs (High Pure Viral Nucleic Acid Kit; Roche). The
primers used in the qPCR were specific for the EF1a promoter:
forward-EF-866, 50-GGTGAGTCACCCACAAAGG-30 and reverse-
EF-931, 50-CGTGGAGTCACATGAAGCGA-30. Vector titers obtained
ranged from 1 1012 to 3 1012 VGs/mL.
SFV VPs were produced from RNA synthetized in vitro using
plasmids pSFV-aPDL1 and pSFV-LacZ as templates. Vector RNA1902 Molecular Therapy Vol. 27 No 11 November 2019synthesis and transfection into BHK-21 cells by electroporation was
performed as described previously.47 For packaging SFV RNA into
VPs, BHK-21 cells were co-electroporated with the recombinant
RNA, together with two helper RNAs (i.e., SFV-helper-C-S219A
and SFV-helper-S2 RNAs), which provided in trans the SFV capsid
and envelope proteins, respectively.48 SFV VPs were harvested and
purified by ultracentrifugation as described previously.49 Indirect
immunofluorescence using a rabbit polyclonal antiserum specific
for the nsp2 subunit of SFV replicase was used as primary antibody50
in SFV-infected BHK-21 cells to determine the titer of each vector.
Vector titers obtained were around 5–8  109 VPs/mL for SFV-
aPDL1 and 2  1010 VPs/mL for SFV-LacZ.
Tumor Induction and Treatment
C57BL/6 female mice were subcutaneously injected with MC38 or
B16-OVA cells (500,000 cells per animal), and vectors were adminis-
tered 7–9 days after tumor inoculation. AAV-aPDL1 (1011 VGs),
SFV-aPDL1 (3  108 VPs), and SFV-LacZ (3  108 VPs) were in-
jected i.t. with a 28G needle in a total volume of 50 mL, using saline
to dilute vectors. Negative control mice were treated with the same
volume of saline. When indicated, three doses of 3  108 VPs of
SFV-aPDL1 were administered i.t. every 48 h.
In experiments where mice received mAbs, the following scheme was
followed: for i.t. administration of anti-PD-L1 mAb, mice received
two i.t. doses of 100 ng of anti-PD-L1 mAb on days 0 and 2 after vec-
tor inoculation. For i.p. administration of anti-PD-L1, mice received
three i.p. doses of 100 mg of mAb on days 0, 3, and 6. In combination
studies, mice received two i.p. doses of 200 mg of anti-CD137 (clone
3H3; Bio X Cell) given on days 0 and 6 after vector inoculation. In
the case of anti-LAG-3 (clone C9B7W; Bio X Cell), mice received
three doses of 200 mg given on days 3, 6, and 9 after vector inoculation.
The efficacy of all treatments was evaluated every 3–4 days by
measuring two perpendicular tumor diameters and considering the
average diameter as an indicator of tumor size and following survival
in each group.
In some experiments, tumors and blood were extracted at the indi-
cated times after treatment. Blood samples were obtained by retro-
orbital venous sinus bleeding and centrifuged at 10,000 rpm for
10 min. Tumor samples were homogenized in 250 mL of PBS-Tween
0.05% in the presence of protease inhibitor cocktail tablets (Roche,
Switzerland), centrifuged at 10,000 rpm for 5 min, and supernatants
were collected for ELISA analysis.
PD-L1 Binding ELISA Assay
Anti-PD-L1mAb in supernatants from transfected (AAV) or infected
(SFV) cells and in sera and tumors from treated mice was determined
by a specific in-house-developed PD-L1-binding ELISA. In brief,
ELISA plates were first coated with 1 mg/mL recombinant murine
PD-L1 fused to human IgG1 Fc (R&D, Minneapolis, MN, USA)
and incubated overnight at 4C. We then incubated plates with serial
dilutions of samples containing anti-PD-L1 mAb. Finally, plates were
www.moleculartherapy.orgincubated with a goat polyclonal secondary antibody anti-mouse
IgG2a conjugated with peroxidase (Abcam, UK), and the assay was
developed with tetramethylbenzidine (TMB) substrate. Then, the
absorbance was measured in an ELISA reader at 450 nm. As standard
curve, we used supernatant from cells transfected with pAAV-aPDL1
in which the concentration of antiPD-L1 mAb was previously quan-
tified with a mouse IgG ELISA kit (Mabtech, Sweden).
Flow Cytometry Analysis
Tumors and TDLNs were treated with 400 U/mL collagenase D and
50 mg/mL DNase I (Roche Diagnostics, Indianapolis, IN, USA). After
mechanical tissue dissociation, cells were passed through a 70-mm
nylon mesh filter (BD Falcon, BD Bioscience, San Jose, CA, USA),
washed, treated with ACK lysing buffer, and washed again. Blood sam-
ples were obtained as described earlier, cells were surface-stained and
then fixed, and erythrocytes were cleared with FACS Lysing Solution
(BD Biosciences). In all cases, a single-cell suspension was pretreated
with anti-CD16/32 (clone 2.4G2; BD Pharmingen) to reduce non-spe-
cific binding to Fc receptors. After this, cells were stained with the
following fluorochrome-conjugated antibodies: CD8 (clone 53-6.7),
CD4 (clone RM4-5), CD62L (clone MEL-14), LAG-3 (clone
C9B7W), CD137 (clone 17B51H1), OX40 (clone OX-86), PD-1 (clone
RMP1-30), PD-L1 (clone 10F.9G2), TIM-3 (clone RMT3-23), ICOS
(clone C398.A4), 2B4 [clone m2B4 (B6)458.1], and CD45 (clone
30F11), all of them from Biolegend (San Diego, CA, USA). To identify
tumor-specific CD8 T lymphocytes, we stained cells with H-2Kb
MuLV p15E Tetramer-KSPWFTTL (MBL International, Woburn,
MA, USA), which comprise an epitope peptide derived from the enve-
lope protein of an endogenous ecotropic murine leukemia virus, which
is expressed in bothMC38 and B16-OVA tumor cells. A FACSCanto II
(BD Biosciences, Franklin Lakes, NJ, USA) was used for cell acquisi-
tion, and data analysis was carried out using FlowJo software
(Tree Star, Ashland, OR, USA).
Statistical Analyses
All data are expressed as the mean ± SEM. Prism software (GraphPad
Software, San Diego, CA, USA) was used for statistical analysis. Sur-
vival of tumor-bearing animals is represented by Kaplan-Meier plots
and was analyzed by log-rank test. To compare experimental groups,
the Kruskal-Wallis test, followed by the Dunn multiple-comparison
test, was used for nonparametric data, and one-way ANOVA, fol-
lowed by the Dunnett’s multiple-comparison test, was used for para-
metric data. For time-series analysis (tumor growth curves), data were
compared using the extra sum-of-squares F test in the Prism software
package and fitted to a second-order polynomial equation. In Figures
1D and 1E, comparisons between saline- and vector-treated mice
were done using the Mann-Whitney U test. The p values <0.05
were considered statistically significant.
Additional Materials and Methods
Determination of the anti-mouse PD-L1 mAb sequence, construction
of SFV and AAV vectors, western blotting, mRNA quantitative ana-
lyses, and in vitro PD-L1 expression are detailed in the Supplemental
Materials and Methods.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.
1016/j.ymthe.2019.09.016.
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